Repligen Corporation (NASDAQ: RGEN) is a Healthcare company in the Medical - Instruments & Supplies industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | 0.73 | Insider Own | 1.14% | Shs Outstand | 56.44M | Perf Week | 7.09% |
| Market Cap | 9.98B | Forward P/E | 67.11 | EPS next Y | 2.64 | Insider Trans | -2.11% | Shs Float | 53.37M | Perf Month | 0.30% |
| Enterprise Value | 9.84B | PEG | 8.95 | EPS next Q | 0.46 | Inst Own | - | Short Float | 12.39% | Perf Quarter | 33.99% |
| Income | 41.00M | P/S | 12.72 | EPS this Y | 182.41% | Inst Trans | - | Short Ratio | 5.97 | Perf Half Y | 50.40% |
| Sales | 785.00M | P/B | 4.73 | EPS next Y | 27.85% | ROA | 1.41% | Short Interest | 6.61M | Perf YTD | 7.95% |
| Book/sh | 37.42 | P/C | 12.32 | EPS next 5Y | 27.08% | ROE | 1.98% | 52W High | 188.72 -6.27% | Perf Year | 48.16% |
| Cash/sh | 14.35 | P/FCF | 84.15 | EPS past 3/5Y | -35.73% -4.98% | ROIC | 1.83% | 52W Low | 100.99 75.16% | Perf 3Y | 11.27% |
| Dividend Est. | - | EV/EBITDA | 80.70 | Sales past 3/5Y | -2.73% 15.06% | Gross Margin | 51.05% | Volatility | 3.40% 3.91% | Perf 5Y | -40.04% |
| Dividend TTM | - | EV/Sales | 12.54 | EPS Y/Y TTM | 258.70% | Oper. Margin | 8.32% | ATR (14) | 6.54 | Perf 10Y | 431.84% |
| Dividend Ex-Date | - | Quick Ratio | 7.64 | Sales Y/Y TTM | 23.82% | Profit Margin | 5.29% | RSI (14) | 59.55 | Recom | 2.04 |
| Dividend Gr. 3/5Y | - | Current Ratio | 9.05 | EPS Q/Q | 45.95% | SMA20 | 1.71% | Beta | 1.09 | Target Price | 162.43 |
| Payout | 0.00% | Debt/Eq | 0.33 | Sales Q/Q | 12.09% | SMA50 | 9.85% | Rel Volume | 1.22 | Prev Close | 178.19 |
| Employees | 2,000 | LT Debt/Eq | 0.32 | Earnings | Nov 03 | SMA200 | 24.32% | Avg Volume | 1.11M | Price | 176.89 |
| IPO Date | Apr 29, 1986 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 20.79% 1.26% | Net Debt/EBITDA | 0.69 | Volume | 1,359,740 | Change | -0.73% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-09-26 | Reiterated | UBS | Buy | $200 → $225 |
| Jul-07-26 | Upgrade | Benchmark | Hold → Buy | |
| Jul-06-26 | Reiterated | Evercore ISI Group | Outperform | $160 |
| May-14-26 | Resumed | RBC Capital | Outperform | $205 → $160 |
| May-05-26 | Reiterated | Jefferies | Hold | $152 → $142 |
| Apr-20-26 | Reiterated | Canaccord Genuity | Hold | $165 → $145 |
| Apr-17-26 | Initiated | Rothschild & Co Redburn | Buy | $160 |
| Apr-14-26 | Reiterated | Barclays | Overweight | $200 → $145 |
| Jan-16-26 | Reiterated | UBS | Buy | $185 → $200 |
| Dec-15-25 | Reiterated | Wells Fargo | Overweight | $190 |
Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 785 | 738 | 634 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 384 | 391 | 360 | — | — | — | — | — | — | |
| Gross Profit | 400 | 348 | 275 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 291 | 291 | 263 | — | — | — | — | — | — | |
| Research and Development | 54 | 54 | 43 | — | — | — | — | — | — | |
| Other Operating Expense | -10 | -57 | 4 | — | — | — | — | — | — | |
| Operating Income | 66 | 60 | -35 | — | — | — | — | — | — | |
| Interest Expense | 22 | 23 | 23 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 9 | 26 | 31 | — | — | — | — | — | — | |
| Net Income Before Taxes | 52 | 62 | -27 | — | — | — | — | — | — | |
| Income Taxes | 10 | 13 | -2 | — | — | — | — | — | — | |
| Consolidated Net Income | 41 | 49 | -26 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 41 | 49 | -26 | — | — | — | — | — | — | |
| Net Income | 41 | 49 | -26 | — | — | — | — | — | — | |
| EPS (Recurring) | 0.74 | 0.87 | -0.46 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 0.74 | 0.87 | -0.46 | — | — | — | — | — | — | |
| EPS (Diluted) | 0.73 | 0.86 | -0.46 | — | — | — | — | — | — | |
| EBITDA | 122 | 164 | 80 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 242.32 | 190.53 | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 12.62 | 12.43 | 12.71 | — | — | — | — | — | — | |
| Gross Margin | 50.96 | 47.15 | 43.38 | — | — | — | — | — | — | |
| Operating Margin | 8.41 | 8.13 | -5.52 | — | — | — | — | — | — | |
| Net Margin | 5.22 | 6.64 | -4.10 | — | — | — | — | — | — | |
| Shares Outstanding | 56 | 56 | 56 | — | — | — | — | — | — | |
| Market Capitalization | 9,906 | 9,176 | 8,061 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Loeillot Olivier | Chief Executive Officer | Sep 04 '26 | Sale | 165.90 | 3,035 | 503,507 | 48,369 | Sep 08 |
| Loeillot Olivier | Chief Executive Officer | Aug 20 '26 | Sale | 180.00 | 5,426 | 976,680 | 54,246 | Aug 21 |
| Loeillot Olivier | Chief Executive Officer | Aug 20 '26 | Option Exercise | 141.79 | 5,426 | 769,353 | 59,672 | Aug 21 |
| Garland Jason K | CFO | Jul 16 '26 | Sale | 150.00 | 530 | 79,500 | 18,829 | Jul 17 |
| Garland Jason K | CFO | Jun 25 '26 | Sale | 145.00 | 733 | 106,285 | 19,359 | Jun 26 |
| MUIR GLENN P | Director | May 07 '26 | Option Exercise | 38.76 | 4,868 | 188,684 | 39,056 | May 08 |
| Loeillot Olivier | Chief Executive Officer | Apr 21 '26 | Sale | 140.00 | 3,832 | 536,480 | 54,246 | Apr 22 |
| DAWES KAREN A | Director | Dec 17 '25 | Sale | 161.00 | 275 | 44,275 | 91,821 | Dec 18 |
| MUIR GLENN P | Director | Dec 16 '25 | Option Exercise | 26.12 | 6,732 | 175,840 | 36,622 | Dec 17 |
| Loeillot Olivier | Chief Executive Officer | Nov 25 '25 | Sale | 170.00 | 7,041 | 1,196,970 | 35,898 | Nov 26 |
| Bylund James | Chief Operating Officer | Nov 18 '25 | Sale | 151.21 | 2,191 | 331,301 | 21,520 | Nov 19 |
| Hunt Anthony | Director | Nov 13 '25 | Sale | 154.61 | 20,000 | 3,092,278 | 80,743 | Nov 14 |
| Hunt Anthony | Director | Nov 13 '25 | Option Exercise | 33.87 | 5,904 | 199,968 | 83,695 | Nov 14 |
| Hunt Anthony | Director | Nov 12 '25 | Option Exercise | 33.87 | 25,000 | 846,750 | 125,743 | Nov 13 |
| Hunt Anthony | Director | Nov 12 '25 | Sale | 156.88 | 25,000 | 3,921,940 | 100,743 | Nov 13 |